Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma

Abstract

In this retrospective study, reduced-dose bevacizumab schedule resulted in similar OS to standard-dose bevacizumab monotherapy with substantial cost savings. MGMT methylation appears to convey a survival benefit in the setting of bevacizumab treatment for progressive GBM.